| Product Name | Rivaroxaban CAS 366789-02-8 |
| Appearance | White powder |
| Molecular formula | C19H18ClN3O5S |
| Molecular Weight | 435.88 |
| Keywords | Rivaroxaban Intermediate;Rivaroxaban Powder;Pharmaceutical Intermediate Rivaroxaban Powder |
| Shelf Life | 24 months when properly stored |
| Storage | Keep in a cool, dry, dark location |
Prevention of Stroke and Systemic Embolism: Rivaroxaban is indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, a common heart rhythm disorder that increases the risk of blood clots forming in the heart.
Treatment and Prevention of Deep Vein Thrombosis (DVT): Rivaroxaban is used to treat DVT, a condition where blood clots form in the deep veins, usually in the legs. Rivaroxaban also helps prevent the recurrence of DVT after an initial episode.
Treatment and Prevention of Pulmonary Embolism (PE): Rivaroxaban is effective in treating PE, a potentially life-threatening condition where a blood clot travels to the lungs. It also helps prevent recurrent PE.
Prevention of Venous Thromboembolism (VTE): Rivaroxaban is used for the prevention of VTE in patients undergoing major orthopedic surgeries, such as hip or knee replacement, where the risk of blood clots is increased.
Prevention of Cardiovascular Events: Rivaroxaban may be used in combination with aspirin to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).
Long-Term Management: Due to rivaroxabans favorable safety profile and lack of need for routine monitoring, Rivaroxaban is suitable for long-term management of patients at risk of thromboembolic events.
Reduced Dietary and Drug Interactions: Rivaroxaban has fewer dietary restrictions and drug interactions, allowing for more flexibility in patient management and adherence.
